p53 Tumor suppressor gene: Implications for iatrogenic cancer and cancer therapy

Medical and Pediatric Oncology

Volumn 27, Issue SUPPL. 1, 1996, Pages 2-11

  De Benedetti, Virna ^a   Bennett, William P ^a   Greenblatt, Marc S ^a   Harris, Curtis C ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; CARCINOGEN;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CIGARETTE SMOKING; CONFERENCE PAPER; ENDOMETRIUM CANCER; HODGKIN DISEASE; HUMAN; IATROGENIC DISEASE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG CANCER; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SKIN CARCINOGENESIS; SKIN CARCINOMA; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS HEPATITIS; COCARCINOGENESIS; FEMALE; GENETICS; MALE; MUTATION; NEOPLASM; REVIEW; SECOND CANCER;

CARCINOGENS; COCARCINOGENESIS; FEMALE; GENES, P53; HUMANS; IATROGENIC DISEASE; MALE; MUTATION; NEOPLASMS; NEOPLASMS, SECOND PRIMARY;

EID: 0029689429     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(1996)27:1+<2::AID-MPO2>3.0.CO;2-Z     Document Type: Conference Paper

References (129)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991.
2. Harris CC: p53: at the crossroads of molecular carcinogenesis and cancer risk assessment. Science 262:1980-1981, 1993.
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991.
4. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 55:4855-4878, 1994.
5. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993.
6. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992.
7. Montenarh M: Functional implications of the growth-suppressor/ oncoprotein p53 [review]. Int J Oncol 1:37-45, 1992.
8. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3547-3551, 1994.
9. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952, 1990.
10. Park M, Vand Woude GF: Principles of molecular cell biology of cancer: oncogenes. In DeVita VT Jr, Hellman S, Rosenberg SA (eds.): "Cancer, Principles & Practice of Oncology." 3rd ed. New York: JB Lippincott Co. 1989, pp. 45-66.
11. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL: Expression of p53 in melanoma. Cancer Res 51:5976-5979, 1991.
12. Council on Scientific Affairs: Harmful effects of ultraviolet radiation. JAMA 262:380-384, 1989.
13. Reid TM, Loeb LA: Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res 52:1082-1086, 1992.
14. Reid TM, Loeb LA: Tandem double CC → TT mutations are produced by reactive oxygen species. Proc Natl Acad Sci USA 90:3904-3907, 1993.
15. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128, 1991.
16. Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK, Yamasaki H: UV and skin cancer; specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91:360-364, 1994.
17. Tomaletti S, Pfeifer GP: Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 263:1436-1438, 1994.
18. Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956, 1988.
19. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:1129-1133, 1981.
20. Koshy R, Hofschneider PH: Transactivation by hepatitis B virus may contribute to hepatocarcinogenesis. Curr Top Microbiol Immunol 144:265-281, 1989.
21. Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317-320, 1991.
22. Feitelson MA, Zhu M, Duan L-X, London WT: Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117, 1993.
23. Wang XW, Forrester K, Yen H, Feitelson MA, Gu JR, Harris CC: Hepatitis B Virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234, 1994.
24. Wogan GN: Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 52:2114s-2118s, 1992.
25. Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA: A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 11:112-119, 1982.
26. Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M: Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 29:545-553, 1987.
27. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF: Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 51:713-726, 1985.
28. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE: Hepatitis V virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 49:2506-2509, 1989.
29. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431, 1991.
30. Challen C, Lunec J, Warren W, Collier J, Bassendine MF: Analysis of the p53 rumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 16:1362-1366, 1992.
31. Hollstein MC, Wild CP, Bleicher F, Chutiwataewin S. Harris CC, Srivatanakul P, Montesano R: p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 53:51-55, 1993.
32. Li D, Cao Y, He L, Wang NJ, Gu J: Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 14:169-173, 1993.
33. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52:6358-6364, 1992.
34. Debuire B, Paterlini P, Pontisso P, Basso G, May E: Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 8:2303-2306, 1993.
35. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen F, Hino O, Smith M, McMahon BJ, Lanier AP, London WT, Redeker AG, Govindarajan S: Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 89:9622-9626, 1992.
36. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late state of hepatocarcinogenesis. Cancer Res 54:231-235, 1994
37. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS: Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 54: 281-285, 1994.
38. Ross RK, Yan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE: Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943-946, 1992.
39. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD: A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3-10, 1994.
40. Pfeifer AMA, Cole KE, Smoot DT, Weston A, Groopman JSD, Shields PG, Vignaud J-M, Juillerat M, Lipsky MM, Trump BF, Lechner JF, Harris CC: SV40 T-antigen immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA 90:5123-5127, 1993.
41. Autrup H, Harris CC, Wu SM, Bao LY, Pei XF, Lu S, Sun TT, Hsia CC: Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. Chem Biol Interact 50:15-25, 1984.
42. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ: Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 87:4790-4793, 1990.
43. Lin JK, Miller JA, Miller EC: 2,3-Dihydro-2(guan-7-yl)-3-hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res 37: 4430-4438, 1977.
44. Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Buchi G, Wogan GN: Structural identification of the major DNA adduct formed by aflatoxin Bl in vitro. Proc Natl Acad Sci USA 74:1870-1874, 1977.
45. 1-induced rat liver tumors. Proc Natl Acad Sci USA 87:1104-1108, 1990.
46. Levy DD, Groopman JD, Lim SE, Seidman MM, Kraemer KH: Sequence specificity of aflatoxin B1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res 52:5668-5673, 1992.
47. Trottier Y, Waithe WI, Anderson A: Kinds of mutations induced by aflatoxin B1 in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. Mol Carcinog 6:140-147, 1992.
48. Aguilar F, Hussain SP, Cerutti P: Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 90:8586-8590, 1993
49. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317-1319, 1994.
50. Shopland DR, Eyre HJ, Pechacek TF: Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142-1148, 1991.
51. Doll R, Peto R: Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health 32:303-313, 1978
52. U.S. Department of Health, Education, and Welfare: Smoking and health. In "A Report of the Surgeon General." DHEW Publication No. (PHS) 79-50066, pp 5-11, 1988.
53. Ronai ZA, Gradia S, Peterson LA, Hecht SS: G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 14:2419-2422, 1993.
54. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R: p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 52:734-736, 1992.
55. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC: p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 342:1520-1521, 1993.
56. Bohr VA, Phillips DH, Hanawalt PC: Heterogeneous DNA damage and repair in the mammalian genome [published erratum appears in Cancer Res 48:1377, 1988. Cancer Res 47:6426-6436, 1987.
57. Hanawalt P, Mellon I: Stranded in an active gene. Curr Biol 3:67-69, 1993.
58. Grafstrom RC, Fornace AJ Jr, Autrup H, Lechner JF, Harris CC: Formaldehyde damage to DNA and inhibition of DNA repair in human bronchial cells. Science 220:216-218, 1983.
59. DeMarini DM: Genotoxicity of tobacco smoke and tobacco smoke condensate. Mutat Res 114:59-89, 1983.
60. McDowell EM, Trump BF: Histogenesis of preneoplastic and neoplastic lesions in tracheobronchial epithelium. Surv Synth Path Res 2:235-279, 1983.
61. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, The H: Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7:1614-1620, 1989.
62. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, Gullo JJ, DiFino SM, Scalzo AJ: The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 7:1398-1406, 1989.
63. Osann KE, Anton-Culver H, Kurosaki T, Taylor T: Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 54:44-48, 1993.
64. Jedrychowski W, Becher H, Wahrendork J, Basa-Cierpialek Z, Gomola K: Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 118:276-282, 1992.
65. Stockwell HG, Goldman AL, Lyman GH, Noss CI, Armstrong AW, Pinkham PA, Candelora EC, Brusa MR: Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst 84:1417-1422, 1992.
66. Harris CC: A delayed complication of cancer therapy - cancer. J Natl Cancer Inst 63:275-277, 1979.
67. Harris CC; Immunosuppressive anticancer drugs in man: their oncogenic potential. Radiology 114:163-166, 1975.
68. Inskip PD, Boice JD Jr: Radiotherapy-induced lung cancer among women who smoke [published erratum appears in Cancer 73: 2456, 1994]. Cancer 73:1541-1543, 1994.
69. Andersson M, Carstensen B, Visfeldt J: Leukemia and other related hematological disorders among Danish patients exposed to thorotrast. Radiat Res 134:224-233, 1993.
70. Popper H, Thomas LB, Telles NC, Falk H, Selikoff IJ: Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic. Comparison with cases of unknown etiology. Am J Pathol 92:349-369, 1978.
71. Falk H, Telles NC, Ishak KG, Thomas LB, Popper H: Epidemiology of thorotrast-induced hepatic angiosarcoma in the United States. Environ Res 18:65-73, 1979
72. DeVita VT Jr, Jaffe ES, Hellman S: Hodgkin's disease and the non-Hodgkin's Lymphomas. In DeVita VT Jr, Hellman S, Rosenberg SA (eds.): "Cancer: Principles and Practices of Oncology." Philadelphia: JB Lippincott Co, 1992, pp. 1623-1737.
73. Bookman MA, Longo DL: Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat Rev 13:77-111, 1986.
74. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988.
75. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986.
76. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboll J, Struck J, Hansen MM, Hansen HH, Nissen NI: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 2:83-88, 1987.
77. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem Oncol 19:47-84, 1992.
78. Van Leeuwen FE, Somers R, Taal BG, van Heerde P, Coster B, Dozeman T, Huisman SJ, Hart AA: Increasing risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 7:1046-1058, 1989.
79. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R. van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R: Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 12:312-325, 1994.
80. Inskip PD, Stovall M, Flannery JT: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 86:983-988, 1994.
81. Neugut AI, Murray T, Santos J, Amols H, Hayes MK, Flannery JT, Robinson E: Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73:1615-1620, 1994.
82. Harvey EB, Brinton LA: Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:99-112, 1985.
83. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318:1028-1032, 1988.
84. Samra Y, Hertz M, Lindner A: Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature. Med Pediatr Oncol 13:86-91, 1985.
85. Fairchild WV, Spence CR, Solomon HD, Gangai MP: The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122:163-164, 1979.
86. Spruck CH III, Rideout WM III, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, Jones PA: Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 53:1162-1166, 1993.
87. Watanabe S, Kobayashi Y. Exogenous hormones and human cancer. Jpn J Clin Oncol 23:1-13, 1993.
88. Yager JD, Campbell HA, Longnecker DS, Roebuck BD, Benoit MC: Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol and mestranol but not estradiol. Cancer Res 44:3862-3869, 1984.
89. Wanless IR, Medline A: Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46:313-320, 1982.
90. Shi YE, Yager JD: Effects of the liver tumor promoter ethinyl estradiol on epidermal growth factor-induced DNA synthesis and epidermal growth factor receptor levels in cultured rat hepatocytes. Cancer Res 49:3574-3580, 1989.
91. Edmondson HA, Henderson B, Benton B: Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 294:470-472, 1976.
92. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW, Jr: Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242:644-648, 1979.
93. Scott LD, Katz AR, Duke JH, Cowan DF, Maklad NF: Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA 251:1461-1463, 1984.
94. Davis M, Portmann B, Searle M, Wright R, Williams R: Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. Br Med J 4:496-498, 1975.
95. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral contraceptive use and liver cancer. Am J Epidemiol 130:878-882, 1989.
96. Yu MC, Tong MJ, Govindarajan S, Henderson BE: Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83:1820-1826, 1991.
97. Forman D, Vincent TJ, Doll R: Cancer of the liver and the use of oral contraceptives. Br Med J (Clin Res Ed) 292:1357-1361, 1986.
98. Jordan VC, Gottardis MM, Satyaswaroop PG: Tamoxifen-stimulated growth of human endometrial carcinoma. Ann NY Acad Sci 622:439-446, 1991.
99. Gibson DF, Gottardis MM, Jordan VC: Sensitivity and insensitivity of breast cancer to tamoxifen. J Steroid Biochem Mol Biol 37:765-770, 1990.
100. Baum M, Odling-Smee W, Houghton J, Riley D, Taylor H: Endometnal cancer during tarrtoxifen treatment. Cancer Research Campaign Breast Cancer Trials Group. Lancet 343:1291, 1994.
101. Bhattacharyya N, Ramsammy R, Batman E, Hollis VW, Anderson WA: Proto-oncogene growth factor, growth factor receptor, and estrogen and progesterone receptor gene expression in the immature rat uterus after treatment with estrogen and tamoxifen. J Submicrosc Cytol Pathol 26:147-162, 1994.
102. Sutherland RL, Lee CS, Feldman RS, Musgrove EA: Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists. J Steroid Biochem Mol Biol 41:315-321, 1992.
103. DeMets DL, Newcomb PA, Carey P: Design issues for a breast cancer chemoprevention trial. Prev Med 20:101-108, 1991.
104. Elias EG, Brown SD, Buda BS, Honts SL: Breast cancer prevention trial. Md Med J 43:249-252, 1994.
105. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991.
106. De Benedetti VMG, Travis LB, Welsh JA, Van Leeuwen FE, Stovall M, Clark EA, Hunter V, Boice JD, Bennett WP: p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev (in press).
107. Waters LC, Sikpi MO, Preston RJ, Mitra S, and Jaberaboansari A: Mutations induced by ionizing radiation in a plasmid replicated in human cells. I. Similar, nonrandom distribution of mutations in unirradiated and X-irradiated DNA. Radiat Res 127:190-201, 1991.
108. Skandalis A, Grosovsky A, Drobetsky EA, Glickman BW: Investigation of the mutagenic specificty of X-rays using a retroviral shuttle vector in CHO cells. Environ Mol Mutagen 20:271-276, 1992.
109. Nelson SL, Giver CR, Grosovsky AJ: A spectrum of X-ray-induced mutations in the human hprt gene. Carcinogenesis 15: 495-502, 1994.
110. Jaberaboansar A, Dunn WC, Preston RJ, Mitra S, Waters LC: Mutations induced by ionizing radiation in a plasmid replicated in human cells. II. Sequence analysis of alpha-particle-mduced point mutations. Radiat Res 127:202-210, 1991.
111. de Jong PJ, Grosovsky AJ, Glickman BW: Spectrum of spontaneous mutation at the APRT Locus of Chinese hamster ovary cells: an analysis at the DNA sequence level. Proc Natl Acad Sci USA 85:3499-3503, 1988.
112. Miles C, Meuth M: DNA sequence determination of gamma-radiation-induced mutations of the hamster aprt locus. Mutat Res 227:97-102, 1989.
113. Grosovsky AJ, de Boer JG, de Jong PJ, Drobetsky EA, Glickman BW: Base substitutions, frameshifts, and small deletions constitute ionizing radiation-induced point mutations in mammalian cells. Proc Natl Acad Sci USA 85:185-188, 1988.
114. Feig DI, Reid TM, Loeb LA: Reactive oxygen species in tumorigenesis. Cancer Res 54:1890s-1894s, 1994.
115. Hussain SP, Aguilar F, Amstad P, Cerutti P: Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. Oncogene 9:2277-2281, 1994.
116. Wyllie AH: Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205-208, 1993.
117. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711, 1994.
118. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML. Wyllie. AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.
119. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
120. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499, 1992.
121. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991.
122. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8:1495-1500, 1993.
123. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA: A retroviral p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129-4133, 1993.
124. Lane DP: The regulation of p53 function: Steiner Award Lecture. Int J Cancer 57:623-627, 1994.
125. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC: Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234, 1994.
126. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121-139, 1992.
127. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54:614-617, 1994.
128. Lowe SW, Ruley HF, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
129. Dowell SP, Hall PA: The clinical relevance of the p53 tumour suppressor gene. Cytopathol 5:133-145, 1994.